ERBB2 and neoplasm: Importantly, we observed a significant reduction in NMuMG-ErbB2 tumour growth (P=8.75 × 10−3, Welch's t-test), whereas tumours from cells additionally expressing Irs4 were unaffected by Lapatinib treatment (Fig. 7j,k).